Results 101 to 110 of about 35,475 (187)

Determination of a suitable voriconazole pharmacokinetic model for personalised dosing

open access: yes, 2016
Model based personalised dosing (MBPD) is a sophisticated form of individualised therapy, where a population pharmacokinetic (PK) or pharmacodynamic model is utilised to estimate the dose required to reach a target exposure or effect. The choice of which
Playford, EG   +3 more
core   +1 more source

Influencing risk factors of voriconazole-induced liver injury in Uygur pediatric patients undergoing allogeneic hematopoietic stem cell transplantation

open access: yesBMC Pediatrics
Purpose We aimed to investigated the influencing risk factors of voriconazole-induced liver injury in Uygur pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Methods This was a prospective cohort design study.
Ting Zhao   +6 more
doaj   +1 more source

Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis

open access: yes, 2018
Javier Martínez-Casanova,1 Nuria Carballo,1 Sonia Luque,1 Luisa Sorli,2 Santiago Grau1 1Pharmacy Department, Hospital del Mar, Barcelona, Spain; 2Infectious Diseases Department, Hospital del Mar, Barcelona, Spain Abstract: Azole antifungals have ...
Santiago Grau   +14 more
core   +1 more source

The Effect of Rifapentine and Rifampicin on Serum Voriconazole Levels Persist for 5 Days and 7 Days or More After Discontinuation in Tuberculosis Patients with Chronic Pulmonary Aspergillosis

open access: yesInfection and Drug Resistance
Hong Lu,* Yanmei Mao,* Ying Zeng, Pengyu Li, Pan Yan, Qunzhi Shi, Lin Liu Department of Pharmacy, The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, People’s Republic of China*These ...
Lu H   +6 more
doaj  

Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use

open access: yes, 2011
In clinical practice, antifungal therapy may be switched from fluconazole to voriconazole; such sequential use poses the potential for drug interaction due to cytochrome P450 2C19 (CYP2C19)-mediated inhibition of voriconazole metabolism. This open-label,
Manthena V. Varma   +2 more
core   +1 more source

Voriconazole is rapidly incorporated.

open access: yes, 2013
Arabidopsis seedlings were incubated for the indicated periods of time in ATS media supplemented with 25 µM voriconazole and the in situ contents of voriconazole were quantified by HPLC-DAD analysis. The means and standard deviations were calculated from
Wilfried Schwab (52238)   +10 more
core   +1 more source

Voriconazole-Induced acute interstitial pulmonary edema with angioedema: A case report

open access: yesBMC Pulmonary Medicine
Background Voriconazole is a first-line antifungal agent for invasive fungal infections. Reports of voriconazole-induced interstitial pulmonary edema are exceedingly rare.
Yuzhen Jin   +4 more
doaj   +1 more source

A Retrospective, Comparative Cohort Analysis of the Utilization of Voriconazole-Containing Regimens Versus Itraconazole in the Treatment of Blastomycosis

open access: yesJournal of Fungi
Itraconazole is the recommended first-line antifungal agent in blastomycosis treatment. However, pharmacokinetic limitations and adverse drug events may necessitate the use of alternative antifungal agents.
Caitlin C. Schanz   +8 more
doaj   +1 more source

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles

open access: yes, 2015
Hyewon Chung,1,* Howard Lee,1,2,* HyeKyung Han,1 Hyungmi An,1 Kyoung Soo Lim,1,3 YongJin Lee,4 Joo-Youn Cho,1 Seo Hyun Yoon,1 In-Jin Jang,1 Kyung-Sang Yu1 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of ...
Jang IJ   +9 more
core  

Drug interactions with voriconazole

open access: yes, 2015
Drug interactions are a potential problem with voriconazole therapy, due to the antifungal's extensive interaction with human cytochrome P450 enzymes and transporters.
VIALE, PIERLUIGI, LEWIS, RUSSEL EDWARD
core  

Home - About - Disclaimer - Privacy